IMPRINT
Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheibio.com
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
SOCIAL MEDIA
© 2022
15th St. Gallen International Breast Cancer Conference 2017, 15-18 March 2017, Vienna, Austria
/in News /by Pantarhei BioscienceThe CSO of Pantarhei, Carole Verhoeven, will attend the St Gallen Breast Cancer Conference in Vienna. She will present a poster summarising the the design of the clinical study with estetrol in patients with advanced breast cancer (ABC E4 study). The hypothesis of this study is that the fetal estrogen estetrol may have anti-tumour effects in patients with advanced ER+ breast cancer and that it most likely will also improve patients quality of life by reducing symptoms of estrogen deficiency. This study will be conducted at three clinical sites in Germany. Enrolment is anticipated to start in April this year.
32nd Annual EAU Congress, March 24-28, 2017, London, UK
/in News /by Pantarhei BiosciencePantarhei Oncology will be visiting the 32nd Annual EAU Congress in London. A poster presentation by Ellen Dutman, CRA at Pantarhei, on Saturday March 25th will show the results of a clinical study with the estrogen E4 in healthy men. The objective of the study was to investigate the efficacy and safety of estetrol for its potential use in the treatment of prostate cancer with special emphasis on the effect of estetrol on testosterone levels. The results suggest that E4 may be suitable for the treatment of advanced prostate cancer.